SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 63.45 |
| Enterprise Value ($M) | 89.46 |
| Book Value ($M) | -24.60 |
| Book Value / Share | -0.54 |
| Price / Book | -2.58 |
| NCAV ($M) | -38.75 |
| NCAV / Share | -0.84 |
| Price / NCAV | -1.64 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.52 |
| Return on Assets (ROA) | -0.32 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.03 |
| Current Ratio | 1.15 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 57.94 |
| Assets | 72.09 |
| Liabilities | 96.69 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Nantahala Capital Management, LLC | 5.80 | ||
| 13G/A | Hirschman Orin | 8.10 | -10.36 | |
| 13D | Soleus Capital Master Fund, L.P. | 10.50 | ||
| 13D | Investissement Quebec | 19.90 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 5,426 | 14,296 | 37.95 | |
| 5,323 | 26,158 | 20.35 | |
| 5,279 | 23,839 | 22.14 | |
| 313 | 2,835 | 11.04 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| TFFP – TFF Pharmaceuticals, Inc. | TGTX – TG Therapeutics, Inc. |
| THAR – Tharimmune, Inc. | TIL – Instil Bio, Inc. |
| TLSA – Tiziana Life Sciences Ltd |
Financial data and stock pages provided by
Fintel.io